Apoptosis in cancer: Key molecular signaling pathways and therapy targets

References

• Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16: 3–11
   PubMed Web of Science ®Google Scholar
• Vanlangenakker N, Berghe TV, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8: 207–20
   PubMed Web of Science ®Google Scholar
• Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784–8
   PubMed Web of Science ®Google Scholar
• Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cell requires caspase-dependent oxidation of high-mobility group Box-1 protein. Immunity 2008; 29: 1–2
   PubMed Web of Science ®Google Scholar
• Birge RB, Ucker DS. Innate apoptotic immunity: The calming touch of death. Cell Death Differ 2008; 15: 1096–102
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nature Rev Mol Cell Biol 2007; 8: 741–52
   PubMed Web of Science ®Google Scholar
• Ullman E, Fan Y, Stawowczyk M, Chen H-M, Yue Z, Zong W-X. Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ 2008; 15: 422–5
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326–36
   PubMed Web of Science ®Google Scholar
• Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51–64
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007; 14: 44–55
   PubMed Web of Science ®Google Scholar
• Kang SJ, Wang S, Kuida K, Yuan J. Distinct downstream pathways of caspase-11 in regulating apoptosis and cytokine maturation during septic shock response. Cell Death Differ 2002; 9: 1115–25
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239–52
   PubMed Web of Science ®Google Scholar
• Vucic D, Franklin MC, Wallweber HJ, Das K, Eckelman BP, Shin H, et al. Engineering MLIAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005; 385: 11–20
   PubMed Web of Science ®Google Scholar
• Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Mol Cell Biol 2005; 6: 287–97
   Google Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007; 131: 669–81
   PubMed Web of Science ®Google Scholar
• Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and independent pathways. Oncogene 2001; 20: 2122–33
   PubMed Web of Science ®Google Scholar
• Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002; 4: 551–7
   PubMed Web of Science ®Google Scholar
• Ndebele, K, Gona, P, Jin, TG, Benhaga, N, Chalah, A, Degli-Esposti, M, , et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipids scramblase-3. Apoptosis 2008;13.
   PubMed Web of Science ®Google Scholar
• Meylan T, Davidson TS, Kahle E, Kinder M, Acharya K, Jankovic D, Bundoc V, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008; 29: 79–89F
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255–60
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462–75
   PubMed Web of Science ®Google Scholar
• Cory S, Adam JM. The Bcl-2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–56
   PubMed Web of Science ®Google Scholar
• Bilyy, R, Kitl, Y, Hellman, U, Stoika, R. AMID: New insights on its intracellular localization and expression at apoptosis. Apoptosis 2008;13.
   PubMed Web of Science ®Google Scholar
• Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304: 437–44
   PubMed Web of Science ®Google Scholar
• Hossini M, Geilen CC, Fecker LF, Daniel PT, Eberle J. A novel Bcl-x splice product, Bcl-xAK triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 2006; 25: 2160–9
   PubMed Web of Science ®Google Scholar
• Dey A, Verma CS, Lane DP. Updates on p53: Modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008; 98: 4–8
   PubMed Web of Science ®Google Scholar
• Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501–14
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3–12
   PubMed Web of Science ®Google Scholar
• Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2008; 15: 21–8
   PubMed Web of Science ®Google Scholar
• Hiroshige N, Mitsuo N. The alteration of Fas receptor and ligand system in hepatocellular carcinoma – How do hepatoma cells escape from the host immune surveillance in vivo?. AINO J 2004; 3: 61–6
   Google Scholar
• Wu Y, Guo E, Yu J, Xie Q. High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol 2008; 31: 79–83
   PubMed Web of Science ®Google Scholar
• Li X, Pan X, Zhang H, Lei D, Liu D, Xu F, et al. Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. J Cancer Res Clin Oncol 2008; 134: 609–15
   PubMed Web of Science ®Google Scholar
• Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by Bcl-2 and Bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513–7
   PubMed Web of Science ®Google Scholar
• Inoue S, Walewska R, Dyer MJS, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008; 22: 819–25
   PubMed Web of Science ®Google Scholar
• Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, et al. Mutation of the bax gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328–30
   PubMed Web of Science ®Google Scholar
• Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriaty R, et al. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007; 71: 101–11
   PubMed Web of Science ®Google Scholar
• Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 2007; 60: 885–95
   PubMed Web of Science ®Google Scholar
• Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, et al. XIAP is highly expressed in esophagean cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 2007; 6: 973–80
   PubMed Web of Science ®Google Scholar
• Richmond A. Nf-Kappa B, chemokine gene transcription and tumor growth. Nat Rev Immunol 2002; 2: 664–74
   PubMed Web of Science ®Google Scholar
• Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–5
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383–5
   PubMed Web of Science ®Google Scholar
• Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, et al. A phase I safety and pharmacokinetics study of recombinant Apo2L/TRAIL an apoptosis inducing protein in patients with advanced cancer. Proc Am Soc Clin Oncol 2006; 24, Abstract 301
   Web of Science ®Google Scholar
• Tolcher AW, Mita M, Meropol NJ, Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390–5
   PubMed Web of Science ®Google Scholar
• Camidge DR, Herbst RS, Gordon M, Eckhardt S, Kurzroc R, Durbin B, et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 2008, Suppl 18: 3582, Abstract 25
   PubMed Web of Science ®Google Scholar
• Sharma S, de Vries EG, Infante JR, Oldenhuis C, Chiang L, Bilic S, et al. Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. J Clin Oncol 2008, Suppl: 3538, Abstract 26
   Web of Science ®Google Scholar
• Saleh MN, Percent I, Wood TE, Posey J, Shah J, Carlisle R, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5) administered weekly to patients with advanced slid tumors or lymphomas. J Clin Oncol 2008, Suppl: 3537, Abstract 26
   Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070–7
   PubMed Web of Science ®Google Scholar
• Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, et al. Direct repression of FLIP expression by myc is a major determinant of TRAIL sensibility. Mol Cell Biol 2004; 24: 8541–55
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, et al. Small-molecules antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25–35
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, et al. Preclinical characterization of AEG35156/GEM 640 a second-generation oligonucleotide targeting X-linked inhibitors of apoptosis. Clin Cancer Res 2006; 12: 5231–41
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, et al. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor family death receptors. Cancer Res 2006; 66: 2367–75
   PubMed Web of Science ®Google Scholar
• Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23–31
   PubMed Web of Science ®Google Scholar
• Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933–8
   PubMed Web of Science ®Google Scholar
• Dey A, Wong ET, Bist P, Tergaonkan V, Lane David P, et al. Nutlin-3 inhibits the NF-κB pathway in a p53-dependent manner: Implication in lung cancer. Ther Cell Cycle 2007; 6: 2178–85
   PubMed Web of Science ®Google Scholar
• Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: A novel biomarker for p53 pathway activation. Mol Cancer Ther 2003; 2: 1023–9
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore JO, Boyd TE. Randomized phase II trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukaemia. J Clin Oncol 2007; 25: 1114–20
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (olimersen sodium) puls dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study. J Clin Oncol 2006; 24: 4738–45
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK, et al. Preclinical studies of the pan-Bcl inhibitor obatolax (GX015-070) in multiple myeloma. Blood 2007; 109: 5430–8
   PubMed Web of Science ®Google Scholar
• Huang Z, Lei X, Zhong M, Zhu B, Tang S, Liao D. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDp cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin 2007; 39: 835–43
   Google Scholar
• Hioki M, Kagawa S, Fujiwara T, Sakai R, Kojima K, Watanabe Y, et al. Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xerografted models. Potential merits and hurdles for combination therapy. Int J Cancer 2008; 122: 2628–33
   PubMed Web of Science ®Google Scholar
• Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403
   PubMed Web of Science ®Google Scholar
• Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Y, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimic GX15-070 (obatoclax). Cancer Res 2008; 68: 3413–20
   PubMed Web of Science ®Google Scholar
• Castro JE, Loria OJ, Aguillon RA, et al. A phase II, open label study of AT101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens. Blood 2007; 110: 917A–918A
   Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–8
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukaemia and lymphoma cells. Cell Death Differ 2008; 15: 820–30
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944–51
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316–25
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–98
   PubMed Web of Science ®Google Scholar
• Davies, AM, Lara, PN, Jr, Mack, PC, Gandara, DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4647–s4651.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai PC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162
   PubMed Web of Science ®Google Scholar
• El-Zawahry A., McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC 2005; 5: 2
   Google Scholar
• Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK, et al. The sequential treatment with ionizing radiation followed by TRAIL/Apo2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004; 24: 1133–40
   PubMed Web of Science ®Google Scholar
• Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005; 10: 1411–8
   PubMed Web of Science ®Google Scholar
• Brooks AD, Ramirez T, Toh U, Onksen J, Elliott P, Murphy WJ, et al. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann NY Acad Sci 2005; 1059: 160–7
   PubMed Web of Science ®Google Scholar
• Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAILinduced apoptosis. Blood 2002; 99: 3419–26
   PubMed Web of Science ®Google Scholar
• Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL – or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808–15
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395–403
   PubMed Web of Science ®Google Scholar